Investment Chapter in EU-India FTA

Implications for Public Health and Access to Medicines

Date
16 June 2011

Presenter
Katrien Vervoort

Oxfam
www.oxfam.org
Background

- Bilateral Investment Treaties
- Lisbon Treaty: FDI becomes exclusive EU competence;
- January 2011: EC request modification negotiating mandate EU-India FTA to include investor protection – under consideration in Council.
- EP resolutions, April and May 2011: need to protect public health
Challenge to regulate in public interest

- Protected investment: Intellectual Property Rights included
- Standards of Protection:
  - Prohibition of « indirect expropriation »
  - Fair and Equitable Treatment
- Enforcement mechanism: investor-state dispute settlement:
  - Bypass domestic courts;
  - Secret nature of investor-state arbitration;
  - High costs;
  - Example of Australia
Some examples

- Philip Morris against Uruguay (Switzerland-Uruguay BIT): tobacco warning as expropriation of trademarks;
- Merck called compulsory license for ARV medicine by Brazil an expropriation of its IP;
- Aguas Argentinas S.A. against Argentina: prize freezing of water prices in economic crisis as unfair and inequitable – compensation to be paid.
Conclusion and Recommendations

• Investment chapter poses a real challenge to health and access to medicines

• Recommended actions:
  • Exclude investor-state arbitration mechanism;
  • Exclude IP from definition of “investment”;
  • Offer precise and narrow definition of “indirect expropriation” and “fair and equitable treatment”.

www.oxfam.org
More information

• CSO briefing note, May 2011: The IP and investment chapters of the EU-India FTA: Implications for Health;
• Oxfam (2011): Sleeping Lions: International investment treaties, state-investor disputes and access to food, land and water.
• Katrien Vervoort, kve@oxfamsol.be
This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission’s or Health & Consumers DG’s views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.